Click here for an archive of Cramer's "Mad Money" recaps.
"It is time to pay a visit to my Wall of Shame for CEOs that are so bad their very presence could bring down a company's stock," Jim Cramer told viewers on his "Mad Money" TV show Friday. "If they just vanished, leaving no one at the helm, their stock could go higher."
Chief Executive Patricia Russo at the top of his list.
After issuing its third profit miss of the year, the company recently had a meeting at which Alcatel's directors asked Russo to come up with an emergency plan to salvage its financial performance, Cramer said.
The Financial Times
has reported the deadline for Russo to come up with this restructuring plan is one month, he said. But if Russo leaves, Cramer believes Alcatel would be better off.
The second slot on the CEO Wall of Shame list, he said, goes to
Marsh & McLennan's
The management at MMC is "in complete and utter disarray," Cramer said, and the turnaround CEO Cherkasky keeps promising keeps taking longer than expected. There are two ways MMC could go higher, he continued. Either Cherkasky could leave or he could announce the breakup of the three different divisions that make up MMC.
Cramer believes if MMC were to be split up, it would be worth 14% more than it is now. He said he came to that conclusion by comparing MMC's segments to its respective peers to see what each broken-up piece is valued at.
Cramer said he knows he used to refer to MMC as one of the great stocks to avoid, but now he believes either Cherkasky could shortly leave the company or it could be broken up.
Cramer presented viewers with
, "a hot, sizzling biotech name" on Speculation Friday.
BioMarin, he said, is the replacement for
, one of his best speculative stocks of the year. Cramer advised buying BioMarin soon, but told viewers to give the stock a week to come in so they don't buy it too high.
BioMarin's drug Kuvan, used in the treatment of phenylketonuria or PKU, an inherited metabolic disease, is the big catalyst that could take this stock higher, he said. There currently is no drug to treat the disease, said Cramer, and patients are usually told to keep a restrictive diet.
Kuvan is expected to cost $25,000 a year, Cramer said. But Cramer believes the price is right because it will be the only drug for PKU allowed on the market.
Biotech companies with pending drug approvals are always speculative, he said, and BioMarin is no different. If Kuvan doesn't get approval, the stock will get hurt badly. But it should get FDA approval by the end of the year, Cramer said.
He said people should consider buying BioMarin for Kuvan because if approved the stock will go much higher. At the same time, it is a risky investment, Cramer warned.
Who Will Take Us to Dow 14,548?
In his "Game Plan" segment, Cramer told viewers the
needs to go up by 653 more points to reach his year-end price target of 14,548.
He came to 14,548, Cramer said by doing a bottoms-up analysis of the Dow stocks. Some of the stocks, like
Procter & Gamble
, said Cramer, already have exceeded his price targets, and will probably go higher.
Other stocks like
are all trading around his individualized targets, he said.
But some stocks, like
Johnson & Johnson
, Cramer expects, will do nothing.
When it comes down to it, Cramer said he believes four names will lead the charge to his target:
, the latter two of which he owns for his charitable trust,
Action Alerts PLUS.
"Those four they will be the four horsemen to take us to the Dow 14,548," Cramer said.
In his "Mad Mail" segment, Cramer said he was wrong to profile
as an ISP company during a recent Lightning Round.
He advised another mailer to wait to buy
, as the stock has been "marked up heavily." The reason AMZN is going up, Cramer explained, is because its revenue id high, costs are low and he expects "a lot is going to fall on the bottom line."
Cramer was bullish on
First Horizon National
Pan American Silver
Cramer was bearish on
Coeur d'Alene Mines
Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by
For more of Cramer's insights during the Lightning Round, click here
At the time of publication, Cramer was long Altria, Caterpillar and McDonald's.
Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for TheStreet.com, Inc., and CNBC, and a director and co-founder of TheStreet.com. All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of TheStreet.com or its affiliates, or CNBC, NBC UNIVERSAL or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither TheStreet.com, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or TheStreet.com is related to the specific opinions expressed by him on "Mad Money."
None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, TheStreet.com or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor TheStreet.com, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.
Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on TheStreet.com. The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in TheStreet.com, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.